DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,298 filers reported holding DANAHER CORPORATION in Q4 2018. The put-call ratio across all filers is 1.15 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,098,239 | +1.8% | 8,398 | +1.8% | 0.30% | -0.7% |
Q1 2024 | $2,060,189 | +0.5% | 8,250 | -6.9% | 0.30% | -5.6% |
Q4 2023 | $2,049,440 | -3.3% | 8,859 | +3.7% | 0.32% | -9.6% |
Q3 2023 | $2,119,765 | +0.3% | 8,544 | -3.0% | 0.35% | +5.0% |
Q2 2023 | $2,113,200 | -4.0% | 8,805 | +0.8% | 0.34% | -9.2% |
Q1 2023 | $2,202,325 | -6.7% | 8,738 | -1.8% | 0.37% | -9.1% |
Q4 2022 | $2,361,441 | +4.5% | 8,897 | +1.7% | 0.41% | -4.4% |
Q3 2022 | $2,260,000 | -1.3% | 8,748 | -3.2% | 0.43% | +4.7% |
Q2 2022 | $2,290,000 | -9.8% | 9,035 | +4.4% | 0.41% | +4.1% |
Q1 2022 | $2,538,000 | -5.3% | 8,655 | +6.2% | 0.39% | -1.0% |
Q4 2021 | $2,681,000 | +18.8% | 8,148 | +9.9% | 0.40% | +8.5% |
Q3 2021 | $2,257,000 | +13.7% | 7,415 | +0.2% | 0.36% | +12.0% |
Q2 2021 | $1,985,000 | +17.9% | 7,398 | -1.1% | 0.33% | +12.4% |
Q1 2021 | $1,683,000 | +1.3% | 7,480 | +0.0% | 0.29% | -3.0% |
Q4 2020 | $1,661,000 | +1.5% | 7,478 | -1.6% | 0.30% | -7.7% |
Q3 2020 | $1,636,000 | +14.0% | 7,601 | -6.3% | 0.32% | +7.6% |
Q2 2020 | $1,435,000 | +32.4% | 8,113 | +3.6% | 0.30% | +13.6% |
Q1 2020 | $1,084,000 | -7.3% | 7,830 | +2.8% | 0.26% | +15.7% |
Q4 2019 | $1,169,000 | +7.9% | 7,614 | +1.6% | 0.23% | +5.5% |
Q3 2019 | $1,083,000 | +72.7% | 7,496 | +71.0% | 0.22% | +52.8% |
Q2 2019 | $627,000 | +10.2% | 4,384 | +1.7% | 0.14% | +9.2% |
Q1 2019 | $569,000 | +36.1% | 4,309 | +6.4% | 0.13% | +22.6% |
Q4 2018 | $418,000 | -2.8% | 4,049 | +2.4% | 0.11% | +15.2% |
Q3 2018 | $430,000 | +13.2% | 3,954 | +2.7% | 0.09% | +5.7% |
Q2 2018 | $380,000 | +0.8% | 3,849 | 0.0% | 0.09% | -1.1% |
Q1 2018 | $377,000 | +5.6% | 3,849 | 0.0% | 0.09% | +8.6% |
Q4 2017 | $357,000 | +11.2% | 3,849 | +2.7% | 0.08% | +5.2% |
Q3 2017 | $321,000 | +1.3% | 3,749 | 0.0% | 0.08% | +1.3% |
Q2 2017 | $317,000 | -1.6% | 3,749 | -0.4% | 0.08% | -3.8% |
Q1 2017 | $322,000 | +9.9% | 3,765 | 0.0% | 0.08% | +11.3% |
Q4 2016 | $293,000 | +6.2% | 3,765 | +6.9% | 0.07% | +6.0% |
Q3 2016 | $276,000 | -30.8% | 3,523 | -10.9% | 0.07% | -54.4% |
Q2 2016 | $399,000 | – | 3,955 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |